RNS Number : 6657X
Hikma Pharmaceuticals Plc
29 December 2023
 

Hikma Pharmaceuticals PLC

(the Company)

Company Secretary Change

 

 

London, 29 December 2023 - Hikma Pharmaceuticals PLC (LEI:549300BNS685UXH4JI75) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) announces that Hussein Arkhagha, Chief People Officer and Company Secretary will step down from his Company Secretary role from 1 January 2024, and will continue in his role as the Chief People Officer of Hikma. Helen Middlemist, Deputy Company Secretary, will be appointed Company Secretary effective same date, 1 January 2024. 

 

 

 

 

 

-- ENDS --

 

Enquiries:

 

Hikma Pharmaceuticals PLC

                                                           

Susan Ringdal, EVP Strategic Planning and Global Affairs                                  +44 (0)20 7399 2760

 

 

 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
COSFLFSVFLLLFIV